One important metric to look for in a stock is an 80 or higher Relative Strength Rating. AstraZeneca ADR stock now clears that threshold, with a jump from 80 to 83 Friday.
This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Is AstraZeneca Stock A Buy?
The IBD 50 stock is trying to complete a cup without handle with an 87.67 buy point. This is not the time to buy stocks during a market correction, but build a watchlist of possible emerging leaders once the market trend turns around.
In terms of revenue and profits, AstraZeneca has posted rising EPS growth over the last two quarters. Sales gains have also risen over the same time frame.
AstraZeneca stock earns the No. 1 rank among its peers in the Medical-Diversified industry group. Abbott Laboratories and Eli Lilly are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
